Mark Leon Siebe, PA-C | |
Blanchfield Army Community Hospital, 650 Joel Dr, Fort Campbell, KY 42223-5318 | |
(270) 798-8727 | |
Not Available |
Full Name | Mark Leon Siebe |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | Blanchfield Army Community Hospital, Fort Campbell, Kentucky |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053801886 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
207Q00000X | Family Medicine | 3649 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mark Leon Siebe, PA-C 1046 Weston Ct, Brentwood, TN 37027-2404 Ph: (615) 630-2250 | Mark Leon Siebe, PA-C Blanchfield Army Community Hospital, 650 Joel Dr, Fort Campbell, KY 42223-5318 Ph: (270) 798-8727 |
News Archive
Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer. That is the conclusion of a recent study published in BJU International.
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.
A new systematic review and meta-analysis showed a small but significant reduction in subjective pain scores for cannabinoid treatment compared to placebo in patients experiencing acute pain.
› Verified 5 days ago